

Cytokeratin 5 [EP1601Y] - 165Ho


Catalog: 716503

Clone: EP1601Y


Isotype: Rabbit IgG

Reactivity: Human*


Application: MIBI-FFPE

Storage: Supplied in antibody stabilizer with 0.05% sodium azide. Store at 4°C



IHC: CK5 staining of FFPE human tonsil



MIBI: CK5 staining (cyan) of FFPE human tonsil, counter-stained with dsDNA (magenta)



IHC: CK5 staining of FFPE human breast



MIBI: CK5 staining (cyan) of FFPE human breast, counter-stained with dsDNA (magenta)

Background

Cytokeratin 5 (CK5) is part of cytoplasmic intermediate filaments that make up the cytoskeleton of basal epithelial/myoepithelial cells. CK5 expression serves as an important diagnostic, prognostic and predictive marker for a variety of cancers including basal-like breast carcinoma, ovarian carcinoma, lung carcinoma and urothelial carcinoma.

Validation

Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIScope analysis using the appropriate positive and negative tissue field of views. These results are pathologist verified.

Recommended Usage

Human FFPE: 1:100 dilution. For optimal results, the antibody should be titrated for each desired application.

References

Silvia Mihaela Illie et al. Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis. *Breast Cancer* (Dove Med Press). 2018; **10**: 177-194.

Corr BR et al. Cytokeratin 5-positive cells represent a therapy resistant subpopulation in epithelial ovarian cancer. *Int J Gynecol Cancer*. 2015 Nov; **25**(9):1565-73.

* Conjugate tested on human tissue.